Mobile website
Clinical Research
Changes in and prognostic value of peripheral blood CD8 + T cells in melanoma patients before and after GVAX treatment
- Article
- Figures
- Metrics
- Preview PDF
- Reference
- Related
- Cited by
- Materials
Abstract:
Objective: To evaluate changes in and prognostic value of CD8+ T cells in the peripheral blood of melanoma patients treated with GM-CSF modified tumor cell vaccine (GVAX). Methods: Fifty-six patients with melanoma who underwent GVAX treatment in the Cancer Institute of Tianjing Medical University between October, 2007 and December, 2012 were enrolled in the study. Proportions of CD3+ lymphocytes, CD4+ T cells, CD8+ T cells, regulatory T lymphocytes (Treg), natural killer cells(NK) and dendritic cell (DC1,DC2) before and after GVAX vaccination treatment were determined by flow cytometry. The relationship between the proportion of CD8+ T cells and other immune cells with patient survival at different post-treatment time points was analyzed. Results: The proportion of CD8+ T cells in peripheral blood was significantly higher (P=0.006) after GVAX treatment (37.56±12.76%) than that before the treatment (3471±12.30%). GVAX treatment resulted in significant decreases in the proportion of CD4+ T cells (P=0.017) and the ratio of CD4+ /CD8+ (P=0.009) but showed no significant effect on the proportions of NK cells, Treg cells, DC1 and DC2 cells (P>0.05). Advanced melanoma patients with a proportion of CD8+ T cells above the mean value before vaccination had better overall survival (29.16 months) compared with those with a lower proportion of CD8+ T cells (1334 months) (P=0.012). Conclusion: GVAX can enhance the ability of CD8+ T cells to induce antitumor immunity. A high proportion of CD8+ T cells before GVAX vaccination is a predictor of better prognosis for patients with advanced melanoma.
Keywords:
Project Supported:
Project supported by the National Basic Research Program of China（973 Program）（No. 2012CB9333004），and the General Program of Basic Research for Application from Committee of Science and Technology of Tianjin City（No. 12JCYBJC16100）
Clc Number:
